Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (II), ~~or a prodrug thereof,~~ or a pharmaceutically acceptable salt thereof ~~of the compound or the prodrug:~~

~~[Formula 1]~~



(II)

where A_1 is C-X_1 ~~or N~~;

Q_1 is ~~$-A_2=A_3-$, or a heteroatom selected from O, S, and $N(R_{10})$~~;

Q_2 is ~~$-A_4=A_5-$, or a heteroatom selected from O, S, and $N(R_{10})$; provided that Q_1 and Q_2 are not heteroatoms at the same time;~~

A_2 is C-X_2 ~~or N~~, A_3 is C-X_3 ~~or N~~, A_4 is C-X_4 ~~or N~~, and A_5 is C-X_5 ~~or N~~;

~~R_{10} is a hydrogen atom, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{1-6}alkylcarbonyl or aryl; the aryl being optionally~~

~~substituted by one or more substituents selected from a halogen atom, C_{1-6}alkyl, and C_{1-6}alkoxy;~~

X_1, X_2, X_3, X_4 and X_5 are each independently selected from the group consisting of a hydrogen atom, hydroxy, a halogen atom, cyano, hydroxyaminocarbonyl, hydroxyamidino, nitro, amino, amidino, guanidino, C_{1-6}alkylamino, diC_{1-6}alkylamino, C_{1-6}alkylamidino, diC_{1-6}alkylamidino, C_{1-6}alkylguanidino, diC_{1-6}alkylguanidino, C_{1-6}alkylthio, C_{1-6}alkylsulfo, C_{1-6}alkylsulfonyl, C_{1-6}alkylphosphono, diC_{1-6}alkylphosphono, C_{1-6}alkyl, C_{1-6}alkoxy, C_{3-9}cycloalkyl, C_{3-9}cycloalkoxy, C_{2-7}alkenyl, C_{2-7}alkynyl, C_{1-6}alkylcarbonyl, C_{1-6}alkoxycarbonyl (the above 19 groups may be substituted by one or more substituents selected from a halogen atom, hydroxy, aryl, heteroaryl, and cyano), aryl, aryloxy, arylcarbonyl, heteroaryl, heteroaryloxy, heteroarylcarbonyl, and arylC_{1-6}alkyloxy (the above 7 groups may be substituted by one or more substituents selected from a halogen atom, C_{1-6}alkyl, and C_{1-6}alkoxy); or

X_1 and X_2, X_2 and X_3, X_3 and X_4, and X_4 and X_5, together with the carbon atoms to which they are bound, form a saturated or unsaturated 5- to 7-membered carbocyclic ring, or a saturated or unsaturated 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom;

Y is selected from the group consisting of ~~C_{1-6}alkyl,~~ C_{3-9}cycloalkyl, C_{2-7}alkenyl, C_{2-7}alkynyl, C_{1-6}alkylcarbonyl, C_{1-6}alkoxycarbonyl, arylcarbonyl, heteroarylcarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, C_{1-6}alkoxy, C_{2-7}alkenyloxy, C_{2-7}alkynyloxy, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl {the above 15 groups may be substituted by one or more substituents selected from a saturated or unsaturated 3- to 7-membered carbocyclyl, a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom, a halogen atom, hydroxy, C_{1-6}alkoxy, hydroxyC_{1-6}alkoxy, C_{1-6}alkoxyC_{1-6}alkoxy, aminoC_{1-6}alkoxy, N-C_{1-6}alkylaminoC_{1-6}alkoxy, N,N-diC_{1-6}alkylaminoC_{1-6}alkoxy, amino, C_{1-6}alkylamino, hydroxyC_{1-6}alkylamino, C_{1-6}alkoxyC_{1-6}alkylamino, aminoC_{1-6}alkylamino, diC_{1-6}alkylamino, bis(hydroxyC_{1-6}alkyl)amino, bis(C_{1-6}alkoxyC_{1-6}alkyl)amino, bis(aminoC_{1-6}alkyl)amino, amidino, C_{1-6}alkylamidino, diC_{1-6}alkylamidino, guanidino, C_{1-6}alkylguanidino, diC_{1-6}alkylguanidino, cyano, carboxyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, C_{1-6}alkylphosphono, and diC_{1-6}alkylphosphono}, amino, C_{1-6}alkylamino, diC_{1-6}alkylamino {the above 2 groups may be substituted by one or more substituents selected from a saturated or unsaturated 3- to 7-membered carbocyclyl, a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms

selected from an oxygen atom, a nitrogen atom, and a sulfur atom, a halogen atom, hydroxy, C_{1-6}alkoxy, hydroxyC_{1-6}alkoxy, C_{1-6}alkoxyC_{1-6}alkoxy, aminoC_{1-6}alkoxy, N-C_{1-6}alkylaminoC_{1-6}alkoxy, N,N-diC_{1-6}alkylaminoC_{1-6}alkoxy, amino, C_{1-6}alkylamino, hydroxyC_{1-6}alkylamino, C_{1-6}alkoxyC_{1-6}alkylamino, aminoC_{1-6}alkylamino, diC_{1-6}alkylamino, bis(hydroxyC_{1-6}alkyl)amino, bis(C_{1-6}alkoxyC_{1-6}alkyl)amino, bis(aminoC_{1-6}alkyl)amino, amidino, C_{1-6}alkylamidino, diC_{1-6}alkylamidino, guanidino, C_{1-6}alkylguanidino, diC_{1-6}alkylguanidino, cyano, carboxyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylthio, C_{1-6}alkylsulfonyl, C_{1-6}alkylphosphono, and diC_{1-6}alkylphosphono), a halogen atom, nitro, cyano, carboxyl, and a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom (the heterocyclyl may be substituted by one or more substituents selected from hydroxy, C_{1-6}alkyl, haloC_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkoxyC_{1-6}alkyl, and oxo);

Z is selected from the group consisting of a hydrogen atom, hydroxy, C_{1-6}alkyl, C_{3-9}cycloalkyl {the above 2 groups may be substituted by one or more substituents selected from a saturated or unsaturated 3- to 7-membered carbocyclyl (the carbocyclyl group may be substituted by one or more substituents selected from C_{1-6}alkyl, hydroxyC_{1-6}alkyl, and

C_{1-6}alkoxyC_{1-6}alkyl), a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom (the heterocyclyl group may be substituted by one or more substituents selected from C_{1-6}alkyl, hydroxyC_{1-6}alkyl, and C_{1-6}alkoxyC_{1-6}alkyl), a halogen atom, hydroxy, C_{1-6}alkoxy, hydroxyC_{1-6}alkoxy, C_{1-6}alkoxyC_{1-6}alkoxy, hydroxyC_{1-6}alkoxyC_{1-6}alkoxy, aminoC_{1-6}alkoxy, N-C_{1-6}alkylaminoC_{1-6}alkoxy, N,N-diC_{1-6}alkylaminoC_{1-6}alkoxy, amino, C_{1-6}alkylamino, hydroxyC_{1-6}alkylamino, C_{1-6}alkoxyC_{1-6}alkylamino, aminoC_{1-6}alkylamino, diC_{1-6}alkylamino, bis(hydroxyC_{1-6}alkyl)amino, bis(C_{1-6}alkoxyC_{1-6}alkyl)amino, bis(aminoC_{1-6}alkyl)amino, cyano, carboxyl, C_{1-6}alkoxycarbonyl, aryloxycarbonyl, carbamoyl, C_{1-6}alkylcarbamoyl, diC_{1-6}alkylcarbamoyl{the above 2 groups may be substituted by one or more substituents selected from a halogen atom, hydroxy, cyano and amino), phosphono, C_{1-6}alkylphosphono, diC_{1-6}alkylphosphono, sulfonic acid, and C_{1-6}alkylsulfo}, and $-OR_1$ and $-NR_1R_2$;

R_1 and R_2 are each dependently selected from the group consisting of a hydrogen atom, C_{1-6}alkyl, C_{1-6}alkylcarbonyl, and a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom (the above 3 groups may be substituted by one or more

substituents selected from a saturated or unsaturated 3- to 7-membered carbocyclyl, a saturated or unsaturated 3- to 7-membered heterocyclyl containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom, a halogen atom, hydroxy, C_{1-6}alkoxy, hydroxyC_{1-6}alkoxy, C_{1-6}alkoxyC_{1-6}alkoxy, aminoC_{1-6}alkoxy, N-C_{1-6}alkylaminoC_{1-6}alkoxy, N,N-diC_{1-6}alkylaminoC_{1-6}alkoxy, amino, C_{1-6}alkylamino, hydroxyC_{1-6}alkylamino, C_{1-6}alkoxyC_{1-6}alkylamino, aminoC_{1-6}alkylamino, diC_{1-6}alkylamino, bis(hydroxyC_{1-6}alkyl)amino, bis(C_{1-6}alkoxyC_{1-6}alkyl)amino, bis(aminoC_{1-6}alkyl)amino, cyano, carboxyl, C_{1-6}alkoxycarbonyl, aryloxycarbonyl, phosphono, C_{1-6}alkylphosphono, diC_{1-6}alkylphosphono, sulfonic acid, and C_{1-6}alkylsulfo); or R_1 and R_2, together with the nitrogen atoms to which they are bound, form a saturated or unsaturated 5- to 7-membered heterocyclic ring containing one nitrogen atom and optionally further containing one or more heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; and

L is selected from the formula:

~~[Formula 2]~~



and


.

2. (Currently Amended) The compound~~, or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to claim 1, wherein the compound is represented by the formula (I):

~~[Formula 3]~~



(I)

where A_1, A_2, A_3, A_4, A_5, L, Y, and Z are as defined in claim 1.

3. (Currently Amended) The compound~~, or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to claim 1 ~~or 2~~, wherein Z is a hydrogen atom, $C_{1\text{-}6}$alkyl, $C_{3\text{-}9}$cycloalkyl, hydroxy$C_{1\text{-}6}$alkyl, hydroxy$C_{1\text{-}6}$alkoxy$C_{1\text{-}6}$alkyl, $C_{1\text{-}6}$alkoxy$C_{1\text{-}6}$alkyl, cyano$C_{1\text{-}6}$alkyl, pyridyl$C_{1\text{-}6}$alkyl, dihydroxy$C_{1\text{-}6}$alkyl, trihydroxy$C_{1\text{-}6}$alkyl, morpholino$C_{1\text{-}6}$alkyl, (N,N-di$C_{1\text{-}6}$alkylamino)$C_{1\text{-}6}$alkyl, or (N,N-bis(hydroxy$C_{1\text{-}6}$alkyl)amino)$C_{1\text{-}6}$alkyl.

4. (Currently Amended) The compound~~, or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to claim 3, wherein Z is a hydrogen atom, methyl, ethyl, cyclopropyl, cyclopentyl, 2-hydroxyethyl, 2-(2-hydroxyethoxy)ethyl, 2-methoxyethyl, 2-cyanoethyl, 4-pyridylmethyl, 1-methoxybut-2-yl, 2,3-dihydroxyprop-1-yl, 1,3-dihydroxyprop-2-yl, 1,3-dihydroxy-2-hydroxymethylprop-2-yl, 2-morpholinoethyl, 1-hydroxyprop-2-yl, 1-hydroxy-3-methylbut-2-yl, 2-(N,N-dimethylamino)ethyl, 2-(N,N-bis(2-hydroxyethyl)amino)ethyl, 2,4-dihydroxylbutyl, 2,3,4-trihydroxybutyl, 2,3,4,5-tetrahydroxypentyl, or 2,3,4,5,6-pentahydroxyhexyl.

5. (Currently Amended) The compound~~, or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to ~~any one of claims~~ claim 1 ~~to 4~~, wherein Y is a halogen atom, cyano, ~~C_{1-6}alkyl, haloC$_{1-6}$alkyl,~~ C_{2-7}alkenyl, C_{2-7}alkynyl, C_{1-6}alkoxy, C_{3-9}cycloalkylC_{1-5}alkoxy, C_{2-7}alkynyloxy, or haloC_{1-6}alkoxy.

6. (Currently Amended) The compound~~, or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to claim 5, wherein Y is chloro, bromo, cyano, ~~methyl, trifluoromethyl,~~

~~ethyl, n-propyl, i-propyl,~~ ethynyl, methoxy, trifluoromethoxy, cyclopropylmethoxy, 2-butyn-1-yloxy, or 2-chloroethoxy.

7. (Currently Amended) The compound~~, or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to claim 1 ~~or 2~~, wherein

~~A_2 is C-X_2 or N, A_3 is C-X_3 or N, A_4 is C-X_4 or N, and A_5 is C-X_5 or N;~~

X_1, X_2, X_3, X_4 and X_5 are each independently selected from a hydrogen atom, a halogen atom, C_{1-6}alkyl, C_{1-6}alkoxy, haloC_{1-6}alkyl, haloC_{1-6}alkoxy, C_{1-6}alkylthio, and haloC_{1-6}alkylthio; or

X_1 and X_2, X_2 and X_3, X_3 and X_4, and X_4 and X_5, together with the carbon atoms to which they are bound, form a cyclohexane ring, a cyclopentane ring, a benzene ring, a pyridine ring, a pyrimidine ring, a 1,4-dioxane ring, a 1,3-dioxolane ring, a pyrrole ring, an imidazole ring, a thiazole ring, or a furan ring.

8. (Currently Amended) The compound~~, or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to claim 7, wherein

X_1, X_2, X_3, X_4 and X_5 are each independently selected from a hydrogen atom, fluoro, chloro, bromo, methyl, ethyl, t-butyl, i-propyl, methoxy, i-propoxy, trifluoromethyl, trifluoromethoxy, methylthio, and trifluoromethylthio; or

X_1 and X_2, together with the carbon atoms to which they are bound, form a cyclohexane ring;

X_1 and X_2, together with the carbon atoms to which they are bound, form a pyridine ring;

X_2 and X_3, together with the carbon atoms to which they are bound, form a 1,4-dioxane ring; or

X_2 and X_3, together with the carbon atoms to which they are bound, form a cyclopentane ring.

9-11. (Cancelled).

12. (Currently Amended) A pharmaceutical composition containing the compound, ~~or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to ~~any one of claims~~ claim 1 ~~to 11~~, as an active ingredient..

13. (Withdrawn-Currently Amended) An angiogenesis inhibitor containing the compound, ~~or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound~~

~~or the prodrug,~~ according to ~~any one of claims~~ claim 1 ~~to 11~~, as an active ingredient.

14. (Withdrawn-Currently Amended) An agent for treatment and prevention of a disease involving angiogenesis, said agent containing the compound, ~~or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to ~~any one of claims~~ claim 1 ~~to 11~~, as an active ingredient.

15. (Withdrawn) The agent for treatment and prevention, according to claim 14, wherein said disease involving angiogenesis is a cancerous disease.

16. (Withdrawn) The agent for treatment and prevention, according to claim 15, wherein said cancerous disease is solid tumor.

17. (Withdrawn-Currently Amended) An agent for treatment and prevention of metastasis of solid tumor, said agent containing the compound, ~~or the prodrug thereof,~~ or the pharmaceutically acceptable salt thereof ~~of the compound or the prodrug,~~ according to ~~any one of claims~~ claim 1 ~~to 11~~, as an active ingredient.